Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

48.73USD
20 Jul 2018
Change (% chg)

$-0.35 (-0.71%)
Prev Close
$49.08
Open
$48.97
Day's High
$49.19
Day's Low
$47.99
Volume
1,403,712
Avg. Vol
1,532,815
52-wk High
$111.36
52-wk Low
$17.52

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $3,878.49
Shares Outstanding(Mil.): 156.33
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -1.40 -- --
ROI: -53.15 2.22 14.61
ROE: -- 3.86 16.34

US STOCKS-Tech rally helps Wall St push higher, Nasdaq has record close

* Indexes gain: Dow 0.72 pct, S&P 0.45 pct, Nasdaq 0.69 pct (Updates to close, adds commentary)

04 Jun 2018

US STOCKS-Technology rally helps Wall Street push higher

* Indexes gain: Dow 0.66 pct, S&P 0.41 pct, Nasdaq 0.57 pct (Updates to late afternoon, adds commentary, changes byline, adds New York dateline)

04 Jun 2018

US STOCKS-Tech rally fuels Nasdaq to near record levels

* Indexes gain: Dow 0.76 pct, S&P 0.42 pct, Nasdaq 0.59 pct (Changes comment, adds details, updates prices)

04 Jun 2018

US STOCKS-Wall Street higher as Apple leads tech rally

* Indexes gain: Dow 0.73 pct, S&P 0.27 pct, Nasdaq 0.28 pct (Changes comment, adds details, updates prices)

04 Jun 2018

Mixed results for Bristol/Nektar combination in cancer trial

Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

04 Jun 2018

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

30 Apr 2018

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

24 Apr 2018

BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21

* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:

01 Mar 2018

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion(1.33 billion pounds) for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

Competitors

Earnings vs. Estimates